

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

	Washington	, D.C.		stimated Average burden hours er response: 4.0
1. Issuer's Identity				
CIK (Filer ID Number)	Previous Name(s)	None	Entity T	ype
0001595097	SAV Acquisition (	Corp	€ Cor	poration
Name of Issuer			_	nited Partnership
Corbus Pharmaceuticals Holdin Inc.	gs,		~	nited Liability Company
Jurisdiction of Incorporation/Organization			~	neral Partnership
DELAWARE			70CC	siness Trust
Year of Incorporation/Organiz	ation		C Oth	er
O Over Five Years Ago				
Within Last Five Years (Specify Year)	2013			
C Yet to Be Formed				
2. Principal Place of Name of Issuer  Corbus Pharmaceuticals Holdin		Contact Inf	ormatio	n
Street Address 1		Street Address 2		
142 WEST 57TH STREET		SUITE 4A		
City	State/Province/Country	ZIP/Postal	Code	Phone No. of Issuer
NEW YORK	NEW YORK	10019		646-367-5905
3. Related Persons				
Last Name	First Name		Middle N	ame
Hochman	David			
Street Address 1		Street Address 2		
142 W. 57th Street		Suite 4A		
City	State/Province/Coun	try	ZIP/Posta	l Code
New York	NEW YORK		10019	

Last Name First Name Middle Name

Hochman David

Street Address 1 Street Address 2

142 W. 57th Street

City State/Province/Country ZIP/Postal Code

New York NEW YORK 10019

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary)

Last Name First Name Middle Name

Cohen Yuval

Street Address 1 Street Address 2

508 Dudley Road

City			State/Province/C	Count	ry	ZIP/Pos	stal Code	
Newton			MASSACHUSETTS		02459	02459		
Relationship:	V	Executiv	ve Officer	V	Director		Promoter	
Clarification of Respon	se (if N	Jecessary)						
ciarineation of Respon	ise (II 1	(cccssary)						
Last Name		1	First Name			Middle	Name	
Tepper			Mark			7		
Street Address 1				S	treet Address 2	<u></u>		
508 Dudley Road				Ī				
City			State/Province/0	<u>L</u> Count	rv	ZIP/Pos	stal Code	
Newton			MASSACHUS			02459		
1100001			1121001101100					
Relationship:	V	Executiv	ve Officer	П	Director		Promoter	
				4	Director		1 Tomotes	
Clarification of Respon	se (if N	Vecessary)						
Last Name			First Name			Middle	Name	
Moran			Sean					
Street Address 1				S	treet Address 2	,		
508 Dudley Road				L				
City	City		State/Province/Country		ZIP/Postal Code			
Newton			MASSACHUS	ETT	S	02459		
Γ	1			1	-		Paux	
Relationship:	₽	Executiv	ve Officer		Director		Promoter	
Clarification of Respon	se (if N	Vecessary)						
Last Name		]	First Name			Middle	Name	
Zurier			Robert					
Street Address 1				S	treet Address 2	<del>_</del>		
303 Martom Rd								
City		4	State/Province/0	Count	ry	ZIP/Pos	stal Code	
Wyckoff			NEW JERSEY		07481			
Relationship:	V	Executiv	ve Officer	П	Director		Promoter	
Clarification of Respon	ise (II N	(ecessary)						
		,					**	
Last Name			First Name			Middle	rvame	
Holmer			Alan					
Street Address 1				S	treet Address 2	; 		<del></del> 1
6 Knight Road				L				
City			State/Province/C			ZIP/Pos	stal Code	
Farmingham			MASSACHUS	ETT	S	01701		

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking	Health Care  © Biotechnology  © Health Insurance  © Retailing  © Restaurants  Technology  © Pharmaceuticals  © Other Health Care
Banking & Financial Services  C Commercial Banking  C Insurance  Investing  C Investment Banking	C Biotechnology C Health Insurance C Hospitals & Physicians C Pharmaceuticals C Computers
C Commercial Banking C Insurance Investing C Investment Banking	C Health Insurance C Restaurants C Hospitals & Physicians Technology C Pharmaceuticals C Computers
C Insurance Investing Investment Banking	C Hospitals & Physicians C Pharmaceuticals C Computers
<ul><li>Investing</li><li>Investment Banking</li></ul>	C Pharmaceuticals C Computers
C Investment Banking	Computers
	Telecommunications
Do alad Invication of Franci	Other Technology
C Pooled Investment Fund	
Other Banking & Financial	Travel
C Services	Manufacturing C Airlines & Airports  Deal Factors  C Lodging & Conventions
Business Services	Real Estate C Lodging & Conventions C Commercial C Tourism & Travel Service
Energy C Coal Mining	C Construction C Other Travel
C Coal Mining  C Electric Utilities	C REITS & Finance C Other
C Energy Conservation	C Residential
C Environmental Services	Other Real Estate
C Oil & Gas	
C Other Energy	
evenue Range  No Revenues	Aggregate Net Asset Value Range  No Aggregate Net Asset Value
\$1 - \$1,000,000	\$1 - \$5,000,000
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$ \$25,000,001, \$100,000,000	
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	S50,000,001 - \$100,000,000 Over \$100,000,000
20	50.000 Market
Over \$100,000,000	Over \$100,000,000

Amendment		
O. D. wation of Official		
8. Duration of Offering	(a)	
Does the Issuer intend this offering to last more than	one year? C Yes No	
O. T. was (a) of Consulting Officers of (		
9. Type(s) of Securities Offered (	select all that apply)	
Pooled Investment Fund Fund Fund Fund Fund Fund Fund Fund		
Tenant-in-Common Securities Debt		
Vilneral Property Securities	varrant or Other Right to nother Security	
Security to be Acquired Upon	•	
Exercise of Option, Warrant or Other (deso Other Right to Acquire Security	cribe)	
10. Business Combination Trans	saction	
Is this offering being made in connection with a busing	iness combination & Yes No	
transaction, such as a merger, acquisition or exchang	ge offer?	
Clarification of Response (if Necessary)	with and into	
At closing, our wholly owned subsidiary merged JB Therapeutics, Inc. and JB became our wholly		
subsidiary. The stockholders of JB received 9,000 our stock and 917,612 warrants exercisable at \$1.	•	
our stock and 517,012 warrants exercisable at \$1.	too per share.	
11. Minimum Investment		
Minimum investment accepted from any outside investor	0 USD	
investor		
12. Sales Compensation		
Recipient	Recipient CRD Number None	
Aegis Capital Corp.	15007	
regio cupran corp.	(Associated) Broker or Dealer CRD	
(Associated) Broker or Dealer   None	Number Number	
	<u> </u>	
Street Address 1	Street Address 2	
Street Address 1	Street Address 2	
810 7th Ave		de
810 7th Ave	18th Floor	de
810 7th Ave City S New York	State/Province/Country  NEW YORK  ZIP/Postal Cod 10019	de
810 7th Ave City S	18th Floor State/Province/Country ZIP/Postal Coo	de
810 7th Ave City S New York	State/Province/Country  NEW YORK  ZIP/Postal Cod 10019	de
810 7th Ave City S New York	State/Province/Country  NEW YORK  ZIP/Postal Cod 10019	de
810 7th Ave City S New York	State/Province/Country  NEW YORK  ZIP/Postal Cod 10019	de
810 7th Ave  City S  New York  State(s) of Solicitation ✓ All States	State/Province/Country   ZIP/Postal Cod   NEW YORK   10019     Foreign/Non-US	de
810 7th Ave City S New York	State/Province/Country   ZIP/Postal Cod   NEW YORK   10019     Foreign/Non-US	de
810 7th Ave  City S  New York  State(s) of Solicitation ✓ All States	State/Province/Country   ZIP/Postal Cod   NEW YORK   10019     Foreign/Non-US	de

Sold	USD ☐ Indefinite
Clarific	cation of Response (if Necessary)
Conte	ets only private placement consideration. emporaneously with the merger, we completed a private ment of stock and warrants. Includes over allotment option.
14.	Investors
	Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,  Number of such non-accredited investors who already have invested in the offering
	Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15.	Sales Commissions & Finders' Fees Expenses
	e separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an iture is not known, provide an estimate and check the box next to the amount.
	Sales Commissions \$ 1300000 USD
	Finders' Fees \$ 0 USD  Estimate
Clarific	cation of Response (if Necessary)
aggre	ment Agent is entitled to receive 10% cash and certain non cash consideration based on the gate amount sold in the offering. Estimated amount of sales commissions assumes maximum ng sold. Includes fees paid on over allotment option.
16.	Use of Proceeds
any of	the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to the persons required to be named as executive officers, directors or promoters in response to Item 3. If the amount is unknown, provide an estimate and check the box next to the amount.
Clariff	\$ USD Estimate
Some for ge	of the proceeds may be used eneral working capital eneral working the proceeds may be used eneral working capital energy include

## Signature and Submission

payment of salaries and other fees

to those listed in Item 3.

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

## Terms of Submission

Total Remaining to be

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
  described and undertaking to furnish them, upon written request, the information furnished to
  offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or
  other legally designated officer of the State in which the Issuer maintains its principal place of
  business and any State in which this notice is filed, as its agents for service of process, and
  agreeing that these persons may accept service on its behalf, of any notice, process or pleading,

and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is
not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii)
or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date	
Corbus Pharmaceuticals Holdings, Inc.	/s/ Yuval Cohen	Yuval Cohen	Chief Executive Officer	2014-04-23	